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The idea that seven transmembrane receptors (7TMRs; also designated G-protein coupled
receptors, GPCRs) might form dimers or higher order oligomeric complexes was formu-
lated more than 20 years ago and has been intensively studied since then. In the last
decade, bioluminescence resonance energy transfer (BRET) has been one of the most
frequently used biophysical methods for studying 7TMRs oligomerization. This technique
enables monitoring physical interactions between protein partners in living cells fused to
donor and acceptor moieties. It relies on non-radiative transfer of energy between donor
and acceptor, depending on their intermolecular distance (1–10 nm) and relative orientation.
Results derived from BRET-based techniques are very persuasive; however, they need
appropriate controls and critical interpretation. To overcome concerns about the speci-
ficity of BRET-derived results, a set of experiments has been proposed, including negative
control with a non-interacting receptor or protein, BRET dilution, saturation, and compe-
tition assays. This article presents the theoretical background behind BRET assays, then
outlines mathematical models for quantitative interpretation of BRET saturation and com-
petition assay results, gives examples of their utilization and discusses the possibilities of
quantitative analysis of data generated with other RET-based techniques.
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INTRODUCTION
Seven transmembrane receptors form the largest and an evo-
lutionarily well conserved family of cell surface receptors, with
more than 800 members identified in the human genome. They
are the targets both for a plethora of endogenous ligands (e.g.,
peptides, glycoproteins, lipids, amino acids, nucleotides, neuro-
transmitters, odorants, ions, and photons) and therapeutic drugs,
and they transduce extracellular (ECL) stimuli into intracellular
(ICL) responses mainly via coupling to guanine nucleotide binding
proteins (G-proteins; McGraw and Liggett, 2006). These receptors
are characterized by seven α-helices, which serve as transmem-
brane spanning domains (TMs) that are connected by three ECL
and three ICL loops. The amino (N)-terminal fragment is ECL
and the carboxyl (C)-terminal tail is ICL. This common structural
topology was resolved by the three-dimensional crystal structure
of individual 7TMR members (reviewed by Salon et al., 2011).
In addition to their well-established ligands and G-proteins, these
receptors can interact with a diverse set of protein partners, includ-
ing G-protein coupled receptor kinases (GRKs), adaptor proteins
such as beta-arrestins, scaffolding proteins that assemble and
localize receptor-signaling complexes in specific cell membrane
microdomains, as well as with each other/other receptor mem-
bers, thereby forming homo-/heteromeric complexes (reviewed by
Maurice et al., 2011). The specificity of agonist-promoted receptor
interactions with protein partners such as GRK2 (Hasbi et al., 2004;
Jorgensen et al., 2008) and β-arrestins (Angers et al., 2000) is not in
doubt and the 7TMR/β-arrestin interaction has been successfully
exploited to develop new bioluminescence resonance energy trans-
fer (BRET)-based screening platforms (Bertrand et al., 2002; Vrecl
et al., 2004, 2009; Hamdan et al., 2005; Heding and Vrecl, 2011). In
contrast, 7TMR homo-/heteromeric complexes are more difficult
to investigate, since these interactions are in general constitutive
and ligand-independent.
METHODOLOGICAL APPROACHES TO STUDYING 7TMRs
DIMERIZATION
Indirect evidence of receptor self-association already existed in
the 1970s, before they were even shown to be seven transmem-
brane receptors (7TMRs). Following classical radioligand studies
on the insulin receptor (De Meyts et al., 1973), negative coop-
erativity, for which dimerization is a prerequisite, was demon-
strated for the β2-adrenergic receptor (β2-AR; Limbird et al.,
1975) and thyrotrophin-stimulating hormone (TSH) receptor
(De Meyts, 1976). In 1982, the receptor mosaic hypothesis was
formulated, which proposed the functional importance of clus-
tered receptors organized by receptor–receptor interaction (Agnati
et al., 1982). Additional evidence supporting 7TMR dimeriza-
tion/oligomerization was provided in the 1970s and 1980s by
the use of radiation inactivation, photo-affinity labeling, cross-
linking, and gel filtration methods (reviewed by Szidonya et al.,
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2008). Trans-complementation studies were subsequently intro-
duced (Maggio et al., 1993a,b) in which co-expression of two non-
functional mutant/chimeric receptors resulted in a gain of func-
tion. Co-immunoprecipitation, which was first utilized to study
β2-AR dimerization (Hebert et al., 1996), was then the most fre-
quently used method for detecting 7TMRs dimerization. Despite
apparent receptor dimerization/oligomerization, there were con-
cerns that higher order structures might be non-specific aggre-
gations following detergent extraction of proteins from cells and
membranes (reviewed by Milligan and Bouvier, 2005). Another
less frequently utilized method for studying 7TMRs dimeriza-
tion is sandwich ELISA (Biebermann et al., 2003; Rediger et al.,
2009). The first widely accepted demonstration of 7TMR hetero-
dimerization came from GABAB receptors, which exclusively func-
tion in a heteromeric form (White et al., 1998). Atomic force
microscopy also demonstrated an oligomeric arrangement of
rhodopsin and opsin in the form of large paracrystalline arrays,
which showed receptors organized into rows of dimers (Liang
et al., 2003; Fotiadis et al., 2004). Again, though, it has been sug-
gested that the observed structure is an artifact of the preparation
process (Chabre et al., 2003; Chabre and le Maire, 2005). Sev-
eral functional studies have also reported co-internalization and
modulation of the signaling activity of hetero-dimers/-oligomers,
supporting the concept of receptor oligomerization (Terrillon and
Bouvier, 2004). The introduction of biophysical techniques based
on resonance energy transfer (RET), such as FRET and BRET,
were then needed for taking the subject of 7TMRs oligomer-
ization to the fore of 7TMRs research, since they enable the
detection of protein–protein interactions in live cells and in real-
time (reviewed by Pfleger and Eidne, 2005). BRET was first
used to demonstrate β2-adrenergic receptor (β2-AR) dimeriza-
tion (Angers et al., 2000) and BRET-based information about
7TMRs homo-/heterodimerization has been rapidly accumulating
since then (for recent reviews see Gurevich and Gurevich, 2008a,b;
Kubale et al., 2008; Ferre et al., 2009; Ayoub and Pfleger, 2010; Ferre
and Franco, 2010; Palczewski, 2010; Achour et al., 2011). Over 20
different biochemical and biophysical methods that have been uti-
lized in 7TMRs oligomerization studies were recently reviewed by
Kaczor and Selent (2011). This review gives a short overview of
BRET technology development and then discusses the possibilities
of quantitative analysis of generated data.
BRET PRINCIPLE AND BRET TECHNOLOGY
DEVELOPMENT/OPTIMIZATION
Bioluminescence resonance energy transfer enables the moni-
toring of physical interactions between two proteins fused to
a BRET donor or acceptor moieties, depending on their inter-
molecular distance (1–10 nm) and relative orientation due to the
dipole-dipole nature of the RET mechanism (Förster, 1959). The
BRET donor is a bioluminescent enzyme (a version of Renilla
luciferase, Rluc), which reacts with the substrate to produce exci-
tation. Part of this excitation can be non-radiatively transferred
by RET to the acceptor molecule, usually a version of the green
fluorescent protein GFP (Figure 1A). In addition to the orig-
inal BRET1 technology (Xu et al., 1999, 2003), which is based
on Rluc as a donor and YFP as an acceptor, several versions of
BRET assays have been developed that use different substrates
and/or energy donor/acceptor pairs (Figure 1B). In BRET2, Rluc
is used as the donor (emission peak 395 nm for coelenterazine
analog DeepBlueC™) and GFP variant two (GFP2) as the accep-
tor molecule (excitation/emission peaks at 400/510 nm). BRET2
enables superior separation of donor and acceptor emission peaks
(Stokes shift of 50 and 115 nm for BRET1 and BRET2, respec-
tively), as well as efficient filtration of the excitation light, thereby
enabling detection of the weak fluorescence signal. The major dis-
advantage of BRET2 compared to BRET1 is the 100–300 times
lower intensity of emitted light and its very fast decay (Heding,
2004). This was improved by the development of suitably sensi-
tive instruments (Heding, 2004) and the use of Rluc mutants with
improved quantum efficiency and/or stability (e.g., Rluc8, Rluc8.6,
and Rluc-M) as donor (De et al., 2007; Loening et al., 2007). The
use of BRET1 and BRET2 is largely limited to in vitro cell culture
systems because they emit light in the green to yellow region of
the visible spectrum (510–570 nm), which is strongly absorbed
by biological tissues such as blood and highly vascularized tissue.
This was overcome by BRET3, which combines Rluc8 with the
mutant red fluorescent protein (DsRed2) variant mOrange and
coelenterazine or EnduRen™ as a substrate (De et al., 2009). In
BRET3, the donor spectrum is the same as in BRET1, and the red
shifted mOrange acceptor signal has excitation/emission peaks at
480/564 nm. Due to tissue attenuation of the light emitted at a
wavelength <600 nm, its utilization in live animals is limited to
superficial locations (e.g., subcutaneous tumors). Recently devel-
oped BRET3 variants (BRET4, BRET5, and BRET6), which have
been optimized for deep-tissue imaging, combine Rluc8/Rluc8.6
with two red fluorescent proteins, i.e., TagRFP (emission peaks at
584 nm) or TurboFP635 (emission peak at 635 nm) and coelenter-
azine or its synthetic derivative (coelenterazine-v) as a substrate
(Dragulescu-Andrasi et al., 2011).
BRET RESULTS – INTERPRETATION AND POSSIBLE
SHORTCOMINGS
The distance (1–10 nm) at which BRET typically occurs is com-
parable with the dimensions of most biological macromolecules
engaged in complex formation or conformational changes, thus
making this technique suitable for monitoring protein–protein
interactions in living cells/organisms (Wu and Brand, 1994). The
experimentally determined Förster distance R0, which leads to
50% of energy transfer from the donor to the acceptor, is 4.4
and 7.5 nm for BRET1 and BRET2, respectively (Dacres et al.,
2010). Even though the working distance of BRET1 is compara-
ble with FRET (4.4 vs. 4.8 nm; Evers et al., 2006), the selection
of RET systems depends on the particular application. FRET,
under microscopic observation, allows visualization of protein
interactions in living cells at the subcellular level, while BRET
might be more suitable for non-imaging applications, such as the
dynamic study of protein–protein interactions in a cell popula-
tion (Boute et al., 2002). Direct comparison of BRET2 with both
FRET and BRET1 showed the superiority of BRET2 over FRET and
BRET1 in proximity-based assays such as protein–protein interac-
tion assays (Dacres et al., 2009a,b). The working distance of 7.5 nm
determined for BRET2 could also make it more suitable for the
study of larger proteins and/or multiprotein complexes, including
7TMR complexes (Dacres et al., 2010). For comparison, the 7TMR
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FIGURE 1 | Schematic representation of the BRET assay and various
BRET variants for studying protein–protein interaction. (A) BRET enables
monitoring of physical interactions between two proteins genetically fused to
donor and acceptor molecules. The BRET donor is a bioluminescent enzyme
(a version of Renilla luciferase, Rluc), which reacts with the substrate to
produce excitation. The acceptor molecule is usually a version of a green
fluorescent protein (GFP). If the distance between donor and acceptor is
more than 10 nm, light is emitted with an emission spectra characteristic for
Rluc. When the distance is less than 10 nm, part of this energy is
non-radiatively transferred by RET from donor (Rluc) to acceptor (version of
GFP), resulting in an additional signal emitted by the acceptor. (B) A summary
of BRET variants and their basic characteristics.
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transmembrane core spans ∼4 nm across the ICL surface (Pal-
czewski et al., 2000), the intradimer distance between rhodopsin
monomers is 3.5 nm and the distance between rhodopsin dimers
is 4.5 nm (Fotiadis et al., 2004). In spite of that, the following lim-
itations of this method need to be considered when interpreting
BRET results. Firstly, the size of fluorescent proteins (∼27 kDa)
and Rluc (∼34 kDa) is comparable to that of the transmembrane
core of 7TMRs (diameter ∼4 nm). These proteins are usually
attached to the receptor C-terminus, which varies in length in
different 7TMRs from 25 to 150 amino acids. Polypeptides of
this length in extended conformation can cover 8-48 nm. A BRET
signal thus indicates that the donor and acceptor moieties are
at distance less than 10 nm, which may occur when receptors
form a structurally defined dimer or when they are >50 nm apart
(reviewed by Gurevich and Gurevich, 2008a). The use of accep-
tor and donor molecules genetically fused to 7TMRs can alter the
functionality of the receptor; fusion proteins can also be expressed
in ICL compartments, making it difficult to demonstrate that the
RET results from a direct interaction of proteins at the cell sur-
face. The use of fusion proteins can therefore be a major limitation
for this application. Secondly, quantitative BRET measurements
are limited by the quality of the signal and noise level. Fluores-
cent proteins and luciferase yield background signals arising from
incompletely processed proteins inside the cell and high cell auto-
fluorescence in the spectral region used (Gurevich and Gurevich,
2008a). Thirdly, so called bystander BRET results from frequent
encounters between over expressed receptors and has no physi-
cal meaning (Kenworthy and Edidin, 1998; Mercier et al., 2002).
Bystander BRET is also problematic when the studied proteins
are confined to a subcellular compartment, such as the plasma
membrane. BRET assays should therefore be able to discriminate
between true dimerization/oligomerization and random collision
due to over-expression. To determine the specificity of a BRET
signal, the following experiments have been proposed: negative
control with a non-interacting receptor or protein, BRET satura-
tion, and competition assays, as well as experiments that observe
ligand-promoted changes in BRET (Ayoub and Pfleger, 2010; Ferre
and Franco, 2010; Achour et al., 2011). Correct execution of these
experiments requires graded control of protein expression over
a broad range of concentration, its accurate measurement, and
knowledge about the subcellular location of the expressed pro-
teins. The choice of appropriate control is also crucially important.
These requirements are not always easy to fulfill in practice and this
further complicates the interpretation of results. A general method
(third-party BRET), which does not require graded expression or
quantification of acceptors or donors, has also been developed
to detect specific constitutive BRET between proteins located in
subcellular compartments of living cells; again, though, it has
the same limitations as other RET methods (Kuravi et al., 2010).
Additionally, proper interpretation of BRET results also requires
quantitative analysis of the result, which has so far only been done
in a small number of studies (Ayoub et al., 2002; Mercier et al.,
2002; Vrecl et al., 2006). The theoretical background of the assays
described below could serve as a guiding principle for the quan-
titative extrapolation of data from BRET experiments performed
with 7TMRs and, presumably, also with other cell surface receptors
that form dimer/oligomers.
BRET MEASUREMENT
In BRET experiments luminescence is measured at the peaks of
donor and acceptor emissions (Xu et al., 1999). Given that a fixed
number of quanta are produced by luciferin-luciferase reactions,
the majority of light is emitted by the donor molecules. If RET
takes place, then part of the energy is transferred to the acceptor
molecules and is emitted at a longer wavelength. Since part of the
donor emission spectra overlaps with the acceptor emission spec-
tra, this background has to be subtracted; the BRET signal is then
calculated as:
BRET =
I2
I1
− I20
I10
, (1)
where I 2 and I 1 are measured luminescences at the two peak posi-
tions in the case of donor-acceptor interactions, and I 10 and I 20
represent luminescence intensities at the two peak positions for
donor only transfected cells. Samples with different concentra-
tions of donors or variations in light quanta produced by the
luciferin-luciferase reaction can in this way be compared.
In order to obtain a correct BRET value that can be compared
between different laboratories, the BRET luminometer should be
properly calibrated, which means that the same proportion of
donor (I 1) and acceptor (I 2) emissions is detected. The sum of
the two emissions is then proportional to the concentration of
donors, which is again proportional to the total luminescence I tot
(luminescence measured in the whole visible spectrum). In gen-
eral, the magnitude of measured luminescence depends on the
selection of emission filters and detector sensitivity. A calibration
factor b is thus introduced:
I1 + b ∗ I2 = k ∗ Itot. (2)
Using the above equation, the value of parameter b can be
assessed by completing two experiments with different donor-
acceptor ratios while measuring I 1, I 2, and I tot. The calibrated
BRET is then:
BRETcal = b ∗
(
I2
I1
− I20
I10
)
. (3)
For conducting BRET assays, information about relative donor
and acceptor concentrations is needed. Donor and acceptor con-
centrations can be assessed by luminescence and fluorescence
measurements, respectively. First, however, the calibration curves
of luminescence and fluorescence vs. receptor concentration must
be obtained by using an immuno-based method or radioligand
binding assay (Ayoub et al., 2002; Mercier et al., 2002; Ramsay
et al., 2004).
BASIC BRET THEORY
Bioluminescence resonance energy transfer is defined as the ratio
between transferred T and not-transferred energy Q:
BRET = T
Q
. (4)
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The probability that excitation is transferred from donor to
acceptor in a single BRET pair is governed by the energy transfer
efficiency E :
T = E ∗ Q0, (5)
where Q0 is total energy (Q0=T +Q). The energy transfer effi-
ciency is inversely proportional to the sixth power of the distance
R between the donor and the acceptor, as described by the Förster
equation (Förster, 1959), where the Förster radius R0 depends on
the spectral overlap and dipole orientations:
E = R
6
0
R60 + R6
. (6)
The calculations in a quantitative BRET assay are derived from
the Veatch and Stryer model (Veatch and Stryer, 1977) covering
FRET experiments with gramicidin dimers. The calculations are
usually simplified by assuming that E is small enough for the
following approximation to be used:
BRETE1 = T
Q0
. (7)
Before using the small energy transfer approximation, the mag-
nitude of the energy transfer efficiency E must be determined.
For dimers, E can be calculated from maximum BRET, which is
obtained when all donor molecules are accompanied by acceptors
(using Eqs 4 and 5):
E = BRETmax
BRETmax + 1
. (8)
QUANTITATIVE BRET ASSAYS
Although determination of the BRET signal is quite simple, the
interpretation of results obtained from oligomerization studies
is not unambiguous. If the receptor expression level is in the
physiological range, there is a problem of distinguishing ran-
dom collisions of donors and acceptors from stable binding. With
increasing receptor concentration, there is a higher probability of
two receptors being in the range of the Förster radius and produc-
ing so called bystander BRET. Several quantitative assays have been
developed to distinguish these two processes, including dilution,
saturation, and competition assays, which allow an assessment of
the receptor oligomerization state and relative affinities for homo-
and hetero-dimer formation (Ayoub et al., 2002; Mercier et al.,
2002). Interpretations of quantitative BRET assays have been sum-
marized in several review articles (Issad and Jockers, 2006; Pfleger
and Eidne, 2006; Ayoub and Pfleger, 2010; Achour et al., 2011;
Kubale et al., 2012).
BRET DILUTION ASSAY
A dilution assay is the simplest control experiment to check for
oligomerization. RET takes place if the distance between donor
and acceptor molecules is in the range of the Förster radius R0.
Molecules can also get close enough for BRET by random colli-
sions (bystander BRET) if their density is high enough (Kenworthy
and Edidin, 1998; Mercier et al., 2002). Excluding random colli-
sions, there should be no concentration dependence for coupled
donor and acceptor molecules. In practice, the BRET signal can be
approximated by:
BRET = BRET0 + k ([D]+ [A]) , (9)
where [D] and [A] are donor and acceptor concentrations. By
simultaneously lowering the concentration of both receptors
(dilution), the BRET signal decreases toward BRET0, which is
the real oligomerization signal (Figure 2). When performing this
experiment, care should be taken to keep the receptor ratio [A]/[D]
constant (Mercier et al., 2002).
There is a low limit of receptor concentrations that can be used
in BRET assays because of the increasing noise in calculated BRET
at low luminescence intensities. The upper limit of the receptor
concentration used in saturation and competition assays should
be set at the point at which the BRET value does not significantly
differ from BRET0. The dilution assay has been used to set the
concentration range for saturation and competition assays and to
distinguish monomers from dimers (Mercier et al., 2002; Terrillon
et al., 2003; Breit et al., 2004; Ramsay et al., 2004).
BRET SATURATION ASSAY
The saturation assay involves expressing a constant amount of
donor-tagged receptor with an increasing amount of acceptor
tagged receptor. Theoretically, the BRET signal should increase
with increasing amounts of acceptor until all donor molecules are
interacting with acceptor molecules. A saturation level BRETmax is
therefore achieved, beyond which a further increase in the amount
of acceptor does not increase the BRET signal (Mercier et al., 2002;
Hamdan et al., 2006; Ayoub and Pfleger, 2010; Achour et al., 2011).
The BRET saturation curve derived from the Veatch and Stryer
model in an approximation of small energy transfer efficiency
FIGURE 2 |Theoretical BRET dilution curves. The ratio between
acceptors and donors is kept constant.
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(Eq. 7) is commonly used:
BRET
BRETmax
= 1− 1(
1 + [A][D]
)N , (10)
N= 1 for dimer, N= 2 for trimer and N= 3 for tetramer. The
detailed derivation can be found in articles by James et al. (2006),
Vrecl et al. (2006). Theoretical BRET saturation curves are pre-
sented in Figure 3. BRET for higher oligomers shows faster satura-
tion. For comparison, the monomer BRET signal that corresponds
to random collisions is presented. If the receptor concentration is
very high, then random collisions can generate a quasi-linear sat-
uration curve similar to that of the dimers. A dilution experiment
should thus be done first to distinguish random collisions from
true oligomerization. Mercier et al. (2002) provided an equation
that differs from that above for N> 1:
BRET
BRETmax
= ([A]+ [D])
N+1 − [A]N+1 − [D]N+1
([A]+ [D])N+1 − [A]N+1 − [D]N+1 + (N + 1) [D]N+1 .
(11)
For dimers, the two equations simplify to a saturation binding
curve that is usually used in saturation assays:
BRET
BRETmax
=
[A]
[D]
1+ [A][D]
. (12)
In Figure 3, a comparison can be made between the theoretical
BRET curve for dimers and quasi-linear curve from non-specific
interactions for which high BRETmax values can be obtained in
FIGURE 3 | BRET saturation assay. Theoretical curves for oligomer
formation are plotted as a function of the ratio of receptors tagged with
acceptor [A] and donor [D] molecules. In the case of monomers, the BRET
signal is created by random collisions.
the case of high receptor concentrations. On the other hand,
the dimer curve remains insensitive to total receptor concen-
tration. For higher oligomers, the saturation curve is shifted to
the left and allows a determination of the oligomerization state
(Mercier et al., 2002; Vrecl et al., 2006). The ability to determine
the oligomerization state from the saturation assay is hampered by
systematic errors in the determination of receptor concentrations
and variations in sample treatments, resulting in a large spread of
data.
BRET50 represents the receptor concentration ratio at which
the saturation curve reaches half-maximum value. The theoretical
BRET50 value for homo-dimers is 1. BRET50 values obtained for
hetero-dimers can be compared with that of homo-dimers as a
measure of the relative affinity for their formation. If the affinity
for hetero-dimer formation is lower, the saturation curve is shifted
to the right, yielding a higher BRET50 value (Mercier et al., 2002;
Terrillon et al., 2003; Breit et al., 2004; Goin and Nathanson, 2006).
In a few cases, the affinity for hetero-dimers is higher than that for
homo-dimers, as shown for melatonin receptors MT2-MT1 and
MT2-MT2 receptor pairs (Ayoub et al., 2004).
The BRETmax value can be used to detect conformational
changes of the receptors forming a certain dimer (Eidne et al.,
2002; Issad and Jockers, 2006). Percherancier et al. (2005) showed
that ligands can cause modulation in the BRETmax without affect-
ing the receptor BRET50 concentration ratio, revealing the change
in energy transfer efficiency E (Eq. 5).
When using a low energy transfer approximation, it should be
checked that E is small (E< 0.2) for all receptor pairs. A general
formula should otherwise be used (see below).
GENERAL BRET SATURATION CURVE
The BRET saturation curve for a general case is derived from the
Veatch and Stryer model using Eq. 4 instead of Eq. 7 (Vrecl et al.,
2006):
BRET
BRETmax
= 1− 1
E + (1− E)
(
1+ [A][D]
)N ; (13)
N represents the oligomerization state: N= 1 for dimer, N= 2
for trimer etc. Figure 4 shows that the saturation curve is shifted
to the right for higher energy transfer efficiencies E, which greatly
affects interpretation of the saturation assay. In several experi-
ments using a small E approximation, it was observed that satura-
tion assay data lay under the theoretical saturation curve (Mercier
et al., 2002; Ramsay et al., 2004; Goin and Nathanson, 2006). The
shift was interpreted as a presence of a monomeric fraction in the
receptor pool, although high E could be responsible for the shift.
BRET COMPETITION ASSAY
In an attempt further to confirm the existence of oligomeric com-
plexes, a competition assay can be performed. In this assay, the
concentration of untagged receptor is increased over the concen-
tration of donor and acceptor tagged receptors (Ayoub et al., 2002;
Devost and Zingg, 2004; Vrecl et al., 2006; Achour et al., 2011). The
BRET signal is expected to decrease if untagged receptors compete
with tagged receptors for binding in complexes. Following the
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FIGURE 4 | Bioluminescence resonance energy transfer saturation
curves for dimers with different energy transfer efficiencies E.
Veatch and Stryer approach (Veatch and Stryer, 1977), the BRET
signal as a function of receptor concentration is obtained (Kubale
et al., 2012):
BRET = T
Q
= E [AD]
2 [DD]+ (1− E) [AD]+ [CD] , (14)
where [C] represents the concentration of untagged competitor.
If all receptors form dimers and association constants are the same
for AA, AD, DD, CD, AC, and CC dimers, the BRET competition
curve for dimers is obtained:
BRETDimer =
E [A][D]
1+ (1− E) [A][D] + [C][D]
. (15)
The competition curve for trimers is obtained in the same way:
BRETTrimer =
2E [A][D]
1+ (1− 2E) [A][D] + [C][D]
. (16)
A high acceptor to donor concentration ratio is commonly used
in BRET saturation experiments, since variations in this ratio do
not influence the BRET signal as much as for [A]/[D]= 1. In gen-
eral, the interaction with untagged receptors causes a reduction
of the BRET signal following a hyperbolic curve (Figure 5). It
can very well be distinguished whether oligomerization is present
but the exact oligomerization state is difficult to assess, because
the dimer and higher oligomer curves are too similar. A compe-
tition assay can be used to study hetero-dimer formation. The
smaller affinity for hetero-dimer formation results in a shallower
competition curve (Figure 5).
In contrast to the hyperbolic competition curve (Eq. 15), a lin-
ear dependence of BRET vs. competitor concentration has been
FIGURE 5 | Bioluminescence resonance energy transfer competition
curves. In a homologous assay, the same kind of receptor is used as a
competitor, whereas in a heterologous assay, a different receptor with a
smaller affinity for hetero-dimer formation is used.
proposed for dimers (Ayoub et al., 2002). In practice, a quan-
titative competition assay is less frequently performed than a
saturation assay due to the need to quantify the untagged com-
petitor concentration using biochemical methods (immuno-based
methods, radioligand binding). Qualitative assays using single wild
type receptor concentrations have been used on several occasions
to assess the specificity of the interaction (Kroeger et al., 2001;
Terrillon et al., 2003; Breit et al., 2004).
CONTROL EXPERIMENTS
A non-interacting receptor should be used for negative control,
which is expressed at similar levels and occupies the same cellular
compartment (Terrillon et al., 2003; Pfleger and Eidne, 2005). For
positive control experiments, donor and acceptor species are fused
together to express a constant BRET signal. This type of experi-
ment is used to test the measurement system and compare data
from different datasets (Pfleger and Eidne, 2006).
NEW RET-BASED TECHNIQUES FOR OLIGOMERIZATION STUDIES
In order to prove higher order oligomerization with more cer-
tainty, new RET-based approaches have been developed that com-
bine two different techniques. A sequential-BRET-FRET (SRET)
has been created that enables identification of hetero-oligomers
formed by three different proteins (Carriba et al., 2008). In SRET,
the oxidation of the Rluc substrate by a Rluc-fusion protein trig-
gers excitation of the acceptor GFP2 by BRET2 and subsequent
energy transfer to the acceptor YFP by FRET. SRET is the ratio
between YFP and Rluc emissions. The experiment is conducted in
the same way as a saturation assay, by measuring SRET with an
increased YFP tagged receptor concentration.
Using the small E approximation and a pure trimer popula-
tion, a SRET curve can be obtained in the same way as those for
www.frontiersin.org August 2012 | Volume 3 | Article 104 | 7
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saturation and competition assays:
SRET
= 2E1E2 [M ] [A]
[D]2 + [M ]2 + [A]2 + 2 [D] [M ]+ 2 [D] [A]+ 2 [M ] [A] ,
(17)
where [D] is the Rluc tagged donor, [M ] is a GFP2 tagged “media-
tor” and [A] is the YFP tagged acceptor. If the donor and mediator
concentrations are kept constant and the acceptor concentration
increased, a rise toward a transient maximum and a decay toward
zero for higher acceptor concentrations should be observed. In
experiments performed by Carriba et al. (2008) only the rising
part of the SRET curve was observed. It can be assumed that higher
acceptor concentrations, for which the decaying part of the SRET
curve should be observed, were not tested.
Other creative approaches to detecting receptor hetero-
dimerization/multiprotein complex formation include combina-
tions of (i) bimolecular luminescence (BiLC) and bimolecular
fluorescence (BiFC), (ii) BiFC and BRET, (iii) GPCR-Heteromer
Identification Technology (GPCR-HIT), and (iv) complemented
donor-acceptor resonance energy transfer (CODA-RET). BiLC
and BiFC enable the detection of tetramer formation (Guo et al.,
2008). Complementary fragments are used to reconstitute the
functional protein when brought into close proximity. A BRET sig-
nal is thus produced only in a protein complex incorporating both
Rluc8 fragments, which act as donors, and both Venus fragments,
which act as acceptors. By increasing the acceptor concentration, it
is possible to observe the BRET concentration dependence, similar
to the standard saturation curve (Eq. 12).
Bimolecular fluorescence in combination with BRET is based
on the ability to produce a fluorescent complex from non-
fluorescent constituents if a protein–protein interaction occurs.
Two receptors are fused at their C-termini with either N-terminal
or C-terminal fragments of YFP, and receptor hetero-dimerization
causes YFP reconstitution. If there is heterotrimerization, BRET
can then be obtained when the cells also co-express the third
receptor fused to Rluc (reviewed by Ferre and Franco, 2010).
GPCR-HIT utilizes BRET and ligand-dependent recruitment of
7TMR-specific interaction partners (such as a β-arrestin, PKC, or
G-protein) to enable 7TMR heteromer discovery and characteri-
zation (Mustafa and Pfleger, 2011; See et al., 2011). In this set up,
only one receptor subtype is fused to Rluc and the second receptor
subtype is untagged. A third protein capable of interacting specif-
ically with one or both receptors in a ligand-dependent manner
is fused to the YFP. The ligand-induced BRET signal indicates
that activation of the untagged receptor or the heteromer results
in recruitment of the YFP tagged protein to the heteromer. The
recently developed CODA-RET method combines protein com-
plementation with RET in order to study conformational changes
in response to activation of a defined 7TMR heteromer. CODA-
RET quantifies the BRET between a receptor heterodimer and a
subunit of the heterotrimeric G-protein. It eliminates the contri-
bution from homodimeric signaling and enables analysis of the
effect of drugs on a defined 7TMR heterodimer (Urizar et al.,
2011).
SUMMARY
Quantitative BRET-based techniques are extremely potent tools
for investigation of membrane receptor interaction in live cells
and in real time, provided they are correctly conducted and data
critically interpreted. A dilution assay is a basic tool for distin-
guishing specific binding from random interaction and is used to
set the receptor concentration range for other BRET assays. Rela-
tive affinities for homo-dimer and hetero-dimer formation can be
investigated using BRET competition and saturation assays. The
latter can also be used to determine the oligomerization state of
the receptors, if the energy transfer efficiency is known and the
correct mathematical model is used. In order unambiguously to
show the formation of trimers and tetramers, the use of methods
that combine different RET-based techniques seems to be more
suitable.
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